Cue Biopharma, Inc.
Cue Biopharma, Inc. (CUE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CUE · as of Jun 9, 2026
Key Statistics
Explore Cue Biopharma, Inc. Data
cue stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 100.0%
The CUE analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $4.33, representing -85.11% downside from the current price of $29.08.
Competitors & Peers
cue competitorsCUE
BRNS
COEP
EQ
IOBT
IPSCStock Performance
Full HistoryAbout Cue Biopharma, Inc.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a…
what is cue biopharma, inc. · cue stock overview · cue biopharma, inc. company profile · who is cue biopharma, inc. ceo · cue NASDAQ · cue biopharma, inc. headquarters · cue biopharma, inc. business segments
About Stock Overview & Key Data
Cue Biopharma, Inc. (CUE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 2, 2018. As of the latest trading session, CUE stock price is $29.08, with a market capitalization of $76.4M. The stock has returned +52.17% over the past 12 months and +217.47% year-to-date.
According to 9 Wall Street analysts, the consensus rating for Cue Biopharma, Inc. stock is Buy, with an average 12-month price target of $4.33. In fiscal year 2025, Cue Biopharma, Inc. reported revenue of $27.5M and net income of -$26.6M. For detailed data — including Cue Biopharma, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Cue Biopharma, Inc. (CUE) stock price is $29.08. The stock is traded on NASDAQ under the ticker symbol CUE. The 52-week range is $4.98 – $41.42.